Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
| Autor: | B. Mlineritsch, Michael Gnant, Richard Greil, Raimund Jakesz, G. Luschin-Ebengreuth, Holger Eidtmann, Herbert Stoeger, Christian F. Singer, S. Poestlberger, P. Dubsky |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Gynecology
Oncology Cancer Research medicine.medical_specialty business.industry Proportional hazards model medicine.medical_treatment Goserelin Anastrozole medicine.disease stomatognathic diseases Zoledronic acid Breast cancer Internal medicine medicine Endocrine system skin and connective tissue diseases business Adjuvant Tamoxifen medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 28:533-533 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2010.28.15_suppl.533 |
| Popis: | 533 Background: The ABCSG-12 trial examined the efficacy of ovarian suppression using goserelin in combination with anastrozole (ANA) or tamoxifen (TAM) ± zoledronic acid (ZOL) in premenopausal patients (pts) with endocrine-responsive breast cancer (EBC). The first efficacy analysis at ASCO 2008, showed no difference between TAM and ANA, but adding ZOL significantly reduced the risk of disease-free survival (DFS) events by 36% (p = 0.01). Longer follow-up is now available. Methods: 1,803 premenopausal pts with EBC were randomized to goserelin (3.6 mg q 28 d) and TAM (20 mg/d) or ANA (1 mg/d) ± ZOL (4 mg q 6 mo). Endpoints were DFS and overall survival (OS); both were analyzed using log-rank test and Cox models. Compared with 2008 data, we now report on 34% more DFS events and 55% more deaths, based on a December 1, 2009, data cutoff. Results: With a median follow-up of 62 mo, 183 DFS events and 65 deaths were reported. Overall, ZOL reduced the risk of DFS events by 32% (HR = 0.68 [95% CI = 0.51, 0.91]; p ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|